Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases

Brain metastases occur in up to 25–55% of patients with metastatic HER2-positive breast cancer. Standard treatment has high rates of recurrence or progression, limiting survival and quality of life in most patients. Temozolomide (TMZ) is known to penetrate the blood–brain barrier and is US FDA appro...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Future Oncol
Auteurs principaux: Zimmer, Alexandra S, Steinberg, Seth M, Smart, Dee Dee, Gilbert, Mark R, Armstrong, Terri S, Burton, Eric, Houston, Nicole, Biassou, Nadia, Gril, Brunilde, Brastianos, Priscilla K, Carter, Scott, Lyden, David, Lipkowitz, Stanley, Steeg, Patricia S
Format: Artigo
Langue:Inglês
Publié: Future Medicine Ltd 2020
Sujets:
Clinical Trial Protocol
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7270957/
https://ncbi.nlm.nih.gov/pubmed/32270710
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon-2020-0094
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires